This research identifies SMARCD3 as a critical epigenetic driver of medulloblastoma metastasis, particularly in the aggressive Group 3 subgroup. Scientists discovered that this protein hijacks a natural neurodevelopmental program—normally used for Purkinje cell migration in the cerebellum—to help cancer cells spread to the brain and spine. By orchestrating chromatin accessibility at specific regulatory sites, SMARCD3 activates the Reelin–DAB1 signaling pathway to increase tumor mobility. The study further reveals that a "chromatin hub" involving EZH2 and NFIX controls the expression of this protein during development and disease. These findings suggest that inhibiting the downstream Src kinase signaling could offer a new therapeutic strategy for patients. Ultimately, the work illustrates how the dysregulation of embryonic biological processes facilitates lethal cancer progression.

References:

• Zou H, Poore B, Brown E E, et al. A neurodevelopmental epigenetic programme mediated by SMARCD3–DAB1–Reelin signalling is hijacked to promote medulloblastoma metastasis[J]. Nature cell biology, 2023, 25(3): 493-507.